Table 4

Immune recognition to sodA peptides among study participants
Subject
 Agea/Sexb/Racec
 Site of Involvementd
 sodA*
 Subject
 Agea/Raceb/Sexc
 Site of Involvementd
 sodA*
Sarcoidosis 6
 50, F, AA
 P, C
 70
 Control 1
 43, F, AA
 None
 0
Sarcoidosis 7
 31, M, AA
 CNS, P, C
 150
 Control 2
 38, F, C
 None
 0
Sarcoidosis 8
 34, F, C
 P
 100
 Control 3
 27, F, AA
 None
 10
Sarcoidosis 9
 55, F, AA
 P
 65
 Control 4
 33, F, AA
 None
 0
Sarcoidosis 10
 56, M, C
 P
 0
 Control 5
 23, M, C
 None
 0
Sarcoidosis 11
 47, F, C
 P, CNS
 0
 Control 6
 25, F, C
 None
 0
Sarcoidosis 12
 42, M, C
 P
 0
 Control 7
 31, M, AA
 None
 0
Sarcoidosis 13
 51, M, AA
 P
 110
 Control 8
 52, F, C
 None
 0
Sarcoidosis 14
 45, M, C
 P, C
 0
 Control 9
 32, F, C
 None
 0
Sarcoidosis 15
 34, F, C
 P
 0
 Control 10
 34, F, AA
 None
 0
Sarcoidosis 16
 30, M, C
 P
 160
 Control 11
 29, M, C
 None
 0
Sarcoidosis 17
 33, M, C
 P
 0
 Control 12
 52, F, C
 None
 0




Control 13
 35, F, C
 None
 0




Control 14
 57, F, C
 None
 0




Control 15
 54, F, C
 None
 0
PPD+ 1
 49, F, C
 Latent
 360
 Control 16
 57, F, C
 None
 10
PPD+ 2
 50, F, AA
 Latent
 50
 Control 17
 55, F, AA
 None
 0
PPD+ 3
 42, F, AA
 Latent
 100
 Control 18
 37, M, AA
 None
 0
PPD+ 4
 58, M, AA
 Latent
 65
 Control 19
 44, F, C
 None
 0
PPD+ 5
 50, F, C
 Latent
 50
 Control 20
 32, F, AA
 None
 0
PPD+ 6
 60, F, AA
 Latent
 0
 Control 21
 32, F, AA
 None
 500
PPD+ 7
 38, F, C
 Latent
 0
 Control 22
 27, F, AA
 None
 0
PPD+ 8
 49, F, C
 Latent
 0
 Control 23
 42, F, AA
 None
 0
PPD+ 9
 42, M, AA
 Latent
 55
 Control 24
 32, M, AA
 None
 0
PPD+ 10
 51, F, C
 Latent
 0
 Control 25
 26, F, AA
 None
 0
PPD+ 11
 30, M, C
 Latent
 0
 Control 26
 50, M, AA
 None
 0

aAge in years; bAA, African-American; C, Caucasian; cF, female, M, male; d P, Pulmonary; C, Cutaneous; CNS, Central Nervous System; ABD, Abdominal; *Inteferon-γ producing spot-forming cells per million PBMC

Allen et al. Respiratory Research 2008 9:36   doi:10.1186/1465-9921-9-36